Literature DB >> 21748440

Androgen receptor coregulators NOCR1, TIF2, and ARA70 may account for the hydroxyflutamide insensitivity of prostate cancer cells.

Y Wang1, J-Q Li, C Shao, C-H Shi, F Liu, Z-Y Yang, J-X Qiu, Y-M Li, Q Fu, W Zhang, W Xue, Y-H Lei, J-Y Gao, J-Y Wang, X-P Gao, J-L Yuan, T-Y Bao, Y-T Zhang.   

Abstract

INTRODUCTION: Prostate cancer cells can switch from an androgen-dependent state to an androgen-independent state after a continuous androgen ablation therapy. However, the molecular mechanisms underlying this switch are still unclear. Therefore, we explored the change in androgen receptor (AR)-related gene expression during this transition in a novel cell model.
MATERIAL AND METHODS: Prostate cancer cells were continuously treated with competitive androgen receptor inhibitor hydroxyflutamide for 1.5 years, which yielded an flutamide-insensitive LNCaP subline, LNCaP-flu, as confirmed by MTT assays, flow cytometry, and electron microscopy. We analyzed the differences in gene expression in LNCaP-flu cells and LNCaP cells using gene chips and follow-up RT-PCR.
RESULTS: Over 2,428 genes were differentially expressed between these cell lines: 1,194 were down-regulated and 1,234 were up-regulated. Three genes in particular were considered related to the androgen-dependent transition: NCOR1, TIF2 (NCOA2), and ARA70 (NCOA4). There were no apparent changes in expression of the androgen receptor or prostate-specific antigen.
CONCLUSION: ARs and associated coregulators play a central role in the flutamide-insensitive transition of prostate cancer cells. Although AR expression does not change during this transition, the change in AR coregulators may be a critical factor in the development of antiandrogen insensitivity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21748440     DOI: 10.1007/s11845-011-0714-4

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  15 in total

1.  [The prostate cancer in the community of Madrid in 2000 I.- Incidence].

Authors:  F Herranz Amo; F Arias Funez; M Arrizabalaga Moreno; F J Calahorra Fernández; J Carballido Rodríguez; R Diz Rodríguez; J A Herrero Payo; C Llorente Abarca; J C Martín Martínez; L Martínez-Piñeiro Lorenzo; R Mínguez Martínez; J Moreno Sierra; A Rodríguez Antolín; J C Tamayo Ruiz; J Turo Antona
Journal:  Actas Urol Esp       Date:  2003-05       Impact factor: 0.994

2.  Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines.

Authors:  F J Drummond; A-E Carsin; L Sharp; H Comber
Journal:  Ir J Med Sci       Date:  2009-06-27       Impact factor: 1.568

3.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

Authors:  C Huggins; C V Hodges
Journal:  CA Cancer J Clin       Date:  1972 Jul-Aug       Impact factor: 508.702

Review 4.  Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer.

Authors:  P Koivisto; T Visakorpi; O P Kallioniemi
Journal:  Scand J Clin Lab Invest Suppl       Date:  1996

5.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.

Authors:  C W Gregory; B He; R T Johnson; O H Ford; J L Mohler; F S French; E M Wilson
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

Review 6.  Castration-resistant prostate cancer: locking up the molecular escape routes.

Authors:  Ricardo M Attar; Chris H Takimoto; Marco M Gottardis
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

Review 7.  Androgen signal transduction and prostatic carcinoma.

Authors:  H Klocker; Z Culig; F Kaspar; A Hobisch; J Eberle; A Reissigl; G Bartsch
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

8.  Ejaculation frequency and subsequent risk of prostate cancer.

Authors:  Michael F Leitzmann; Elizabeth A Platz; Meir J Stampfer; Walter C Willett; Edward Giovannucci
Journal:  JAMA       Date:  2004-04-07       Impact factor: 56.272

9.  The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP.

Authors:  N Olea; K Sakabe; A M Soto; C Sonnenschein
Journal:  Endocrinology       Date:  1990-03       Impact factor: 4.736

10.  Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase.

Authors:  Chen Shao; Yong Wang; Hong-Hong Yue; Yun-Tao Zhang; Chang-Hong Shi; Fan Liu; Ting-Yi Bao; Zeng-Yue Yang; Jian-Lin Yuan; Guo-Xing Shao
Journal:  J Androl       Date:  2007-06-20
View more
  3 in total

1.  Gelfoam embolization or 125I seed implantation may be a more effective treatment than surgical treatment for giant benign sacral neurogenic tumors.

Authors:  Xiaojun Ma; Sun Wei; Chunxi Yang; Yingqi Hua; Jiakang Shen; Zhengdong Cai
Journal:  World J Surg Oncol       Date:  2015-08-15       Impact factor: 2.754

2.  A meta-analysis of multiple matched copy number and transcriptomics data sets for inferring gene regulatory relationships.

Authors:  Richard Newton; Lorenz Wernisch
Journal:  PLoS One       Date:  2014-08-22       Impact factor: 3.240

3.  Genistein sensitizes bladder cancer cells to HCPT treatment in vitro and in vivo via ATM/NF-κB/IKK pathway-induced apoptosis.

Authors:  Yong Wang; He Wang; Wei Zhang; Chen Shao; Peng Xu; Chang Hong Shi; Jian Guo Shi; Yu Mei Li; Qiang Fu; Wei Xue; Yong Hua Lei; Jing Yu Gao; Juan Ying Wang; Xiao Ping Gao; Jin Qing Li; Jian Lin Yuan; Yun Tao Zhang
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.